Received Aug 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVB064A | — |
A 16-year-old female patient received the powder portion of Menveo reconstituted with normal saline water.; A 16-year-old female patient received the powder portion of Menveo reconstituted with normal saline water.; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 16-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB064A, expiry date 31-DEC-2025) for prophylaxis. On 24-JUL-2025, the patient received Menveo. On 24-JUL-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: A 16-year-old female patient received the powder portion of Menveo reconstituted with normal saline water.) and inappropriate dose of vaccine administered (Verbatim: A 16-year-old female patient received the powder portion of Menveo reconstituted with normal saline water.). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 24-JUL-2025 Registered Nurse called to report that Menveo lyophilized component was reconstituted using normal saline water instead of the diluent provided, which led to wrong solution used in drug reconstitution and Inappropriate preparation of medication. The reporter wanted to ask if the patient needs to wait 28 days before giving a repeat dose or not. The reporter consented to follow up.